Nordic Life Science
Pharma
Latest Pharma News
Swedish Affibody and US Alexion Pharmaceuticals have announced a partnership to co-develop ABY-039 for rare Immunoglobulin G (IgG)-mediated autoimmune diseases. Under the terms of the agreement, Alexion will provide Affibody
The company will evaluate a possible listing of its shares on Nasdaq Stockholm’s Main Market during 2020 and will engage advisors to explore this potential relisting. LIDDS is in a
The Finnish biotech company has announced a positive outcome of a directed share issue, gaining additional support from long-term strategic institutional investors. The share capital will not be increased. Instead,
The company has announced the appointment of Keld Flintholm Jørgensen to the role of Chief Business Officer (CBO) heading Corporate Strategy & Business Development from 4 April 2019. Keld will
Orion Corporation and Bayer have announced that a marketing authorization application (MAA) has been submitted to the European Medicines Agency (EMA) for darolutamide for the treatment of patients with non-metastatic castration-resistant
Swedish drug development company Modus Therapeutics has had a busy year, and 2019 could take them one step closer to having sevuparin on the market. In 2016 the clinical-stage drug
Clinical trials
The company will present these preclinical data for the drug candidate ATOR-1017 at the 4th Annual Immuno-oncology Summit Europe, to
The company has announced the dosing of the first patient in their first Phase 3 trial to evaluate dasiglucagon as
The first patient has successfully been dosed in the company’s phase I study of ATOR-1015, its drug candidate in development
The first cohort has been successfully dosed in the Phase 1, single ascending dose study to explore the pharmacokinetics and
The last patient has been enrolled in the company’s study for the localized treatment of prostate cancer. The Phase IIb
Data from the company’s Phase II HORIZON study and Phase I/II ANCHOR study evaluating the company’s novel candidate melflufen have
The biopharmaceutical company announces the completion of enrollment in their Phase II proof-of-concept study of ABY-035 for moderate-to-severe psoriasis, AFFIRM-35.
AstraZeneca and MSD have announced positive results from the Phase III POLO trial. Results from the trial showed a statistically-significant
The Swedish clinical-stage biotech company Sigrid Therapeutics has, together with Crown CRO, announced the initiation of the STAR clinical trial,
The first patient has been dosed in a Phase 1/2a clinical study evaluating a prime-boost vaccine regimen based on Janssen’s
The Phase III THEMIS trial met its primary endpoint and demonstrated that Brilinta (ticagrelor), taken in conjunction with aspirin, showed
The company has received approval from the Swedish Medical Products Agency to initiate the first clinical trial with the contrast
Orion’s and Bayer’s darolutamide shows substantial efficacy and a favourable safety profile in the treatment of prostate cancer in the
Lundbeck and Otsuka report new data from their trials evaluating brexpiprazole for the treatment of manic episodes associated with bipolar
The first patient has been treated in the Phase Ib/II ILIAD clinical trial evaluating the safety and efficacy of Immunicum’s lead
First presentation of data from the Phase III ARAMIS trial with the investigational compound darolutamide in patients with advanced prostate
Pharma articles
Immunotherapy is the 2016 Clinical Cancer Advance of the Year and a promising new strategy for treating cancer. But how far have we come? The American Society of Clinical Oncology
The high cost and uncertain outcomes of developing new drugs has taken a toll on research over the past several years. Few companies can take the hit of investing hundreds
Liquid biopsies, sequencing and upgraded software tools are among some of the recent and ongoing trends in cancer diagnostics. Developments in the diagnostic sector have vastly improved the ability to
The rapid development within nanotechnology drug delivery is creating new possibilities to treat common diseases and improving pharmaceuticals. Safety aspects and competitionwith established treatments are however some of the obstacles
Hans Lennernäs, professor in biopharmaceutics at Uppsala University, has extensive experience in developing drug delivery methods. NLS asked him about his research and ongoing activities in the field. He spoke
Much effort is being made to develop new medicines for diabetes and recent findings indicate the potential for new and improved pharmaceuticals. Diabetes is one of the largest global diseases
Profiles in Pharma
“It is with great regret and sadness we announce this very tragic and unexpected information,” says the Board of Directors,
In an interview in Nordic Life Science, the Head of AstraZeneca’s Oncology Business unit, shared his insights on current drug
Ironically, there is less serendipity in the success Saeid Esmaeilzadeh and Ashkan Pouya have achieved as business-makers than there is
Bahija Jallal’s curiosity and passion for science have been strong driving forces throughout her entire career, as has her belief
After ten years of diabetes research and development at Novo Nordisk, Dorte X. Gram took her findings and work further
Mads Krogsgaard Thomsen, Executive Vice President and Chief Science Officer at Novo Nordisk, talks about the Danish pharma giant’s drug-development
Logistics
With a deadline looming to meet a new EU Falsification Medicines Directive (FMD) by 2019, there is no shortage of challenges for packaging experts. Besides satisfying EU requirements, drug manufacturers
Packaging is an often overlooked element of the life science supply chain but the industry needs to step up quality and foster innovation in order to keep up with developments